BeiGene, Ltd., a global oncology-focused biopharma, announced FDA's fast-track approval for its cancer drug BRUKINSA(zanubrutinib).

Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.

Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.

VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.

Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.

Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.

Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.

Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.

LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.

Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.